GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Forward PE Ratio

HURA (TuHURA Biosciences) Forward PE Ratio : 0.00 (As of Dec. 12, 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Forward PE Ratio?

TuHURA Biosciences's Forward PE Ratio for today is 0.00.

TuHURA Biosciences's PE Ratio without NRI for today is 0.00.

TuHURA Biosciences's PE Ratio (TTM) for today is 0.00.


TuHURA Biosciences Forward PE Ratio Historical Data

The historical data trend for TuHURA Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Forward PE Ratio Chart

TuHURA Biosciences Annual Data
Trend
Forward PE Ratio

TuHURA Biosciences Semi-Annual Data
Forward PE Ratio

Competitive Comparison of TuHURA Biosciences's Forward PE Ratio

For the Biotechnology subindustry, TuHURA Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TuHURA Biosciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's Forward PE Ratio falls into.



TuHURA Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


TuHURA Biosciences  (NAS:HURA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


TuHURA Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.